Martha M S Sim1, Meenakshi Banerjee1,2, Thein Myint3,4, Beth A Garvy5, Sidney W Whiteheart1,6, Jeremy P Wood1,7,8. 1. Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY. 2. Department of Internal Medicine and Molecular Medicine Program, University of Utah, Salt Lake City, UT. 3. Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky, Lexington, KY. 4. Bluegrass Care Clinic, Kentucky Clinic, University of Kentucky, Lexington, KY. 5. Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY. 6. Lexington Veterans' Affairs Healthcare System, Lexington, KY. 7. Gill Heart and Vascular Institute, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Kentucky, Lexington, KY; and. 8. Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY.
Abstract
BACKGROUND: HIV-1 infection is associated with multiple procoagulant changes and increased thrombotic risk. Possible mechanisms for this risk include heigthened expression of procoagulant tissue factor (TF) on circulating monocytes, extracellular vesicles, and viral particles and/or acquired deficiency of protein S (PS), a critical cofactor for the anticoagulant protein C (PC). PS deficiency occurs in up to 76% of people living with HIV-1 (PLWH). As increased ex vivo plasma thrombin generation is a strong predictor of mortality, we investigated whether PS and plasma TF are associated with plasma thrombin generation. METHODS: We analyzed plasma samples from 9 healthy controls, 17 PLWH on first diagnosis (naive), and 13 PLWH on antiretroviral therapy (ART). Plasma thrombin generation, total and free PS, PC, C4b-binding protein, and TF activity were measured. RESULTS: We determined that the plasma thrombin generation assay is insensitive to PS, because of a lack of PC activation, and developed a modified PS-sensitive assay. Total plasma PS was reduced in 58% of the naive and 38% of the ART-treated PLWH samples and correlated with increased thrombin generation in the modified assay. Conversely, plasma TF was not increased in our patient population, suggesting that it does not significantly contribute to ex vivo plasma thrombin generation. CONCLUSION: These data suggest that reduced total plasma PS contributes to the thrombotic risk associated with HIV-1 infection and can serve as a prothrombotic biomarker. In addition, our refined thrombin generation assay offers a more sensitive tool to assess the functional consequences of acquired PS deficiency in PLWH.
BACKGROUND: HIV-1 infection is associated with multiple procoagulant changes and increased thrombotic risk. Possible mechanisms for this risk include heigthened expression of procoagulant tissue factor (TF) on circulating monocytes, extracellular vesicles, and viral particles and/or acquired deficiency of protein S (PS), a critical cofactor for the anticoagulant protein C (PC). PS deficiency occurs in up to 76% of people living with HIV-1 (PLWH). As increased ex vivo plasma thrombin generation is a strong predictor of mortality, we investigated whether PS and plasma TF are associated with plasma thrombin generation. METHODS: We analyzed plasma samples from 9 healthy controls, 17 PLWH on first diagnosis (naive), and 13 PLWH on antiretroviral therapy (ART). Plasma thrombin generation, total and free PS, PC, C4b-binding protein, and TF activity were measured. RESULTS: We determined that the plasma thrombin generation assay is insensitive to PS, because of a lack of PC activation, and developed a modified PS-sensitive assay. Total plasma PS was reduced in 58% of the naive and 38% of the ART-treated PLWH samples and correlated with increased thrombin generation in the modified assay. Conversely, plasma TF was not increased in our patient population, suggesting that it does not significantly contribute to ex vivo plasma thrombin generation. CONCLUSION: These data suggest that reduced total plasma PS contributes to the thrombotic risk associated with HIV-1 infection and can serve as a prothrombotic biomarker. In addition, our refined thrombin generation assay offers a more sensitive tool to assess the functional consequences of acquired PS deficiency in PLWH.
Authors: Angeles Alvarez; Cesar Rios-Navarro; Maria Amparo Blanch-Ruiz; Victor Collado-Diaz; Isabel Andujar; Maria Angeles Martinez-Cuesta; Samuel Orden; Juan V Esplugues Journal: Antiviral Res Date: 2017-03-02 Impact factor: 5.970
Authors: Mark T Cunningham; John D Olson; Wayne L Chandler; Elizabeth M Van Cott; Charles S Eby; Jun Teruya; Sandra C Hollensead; Dorothy M Adcock; Paul M Allison; Kandice K Kottke-Marchant; Marc D Smith Journal: Arch Pathol Lab Med Date: 2011-02 Impact factor: 5.534
Authors: William E Plautz; Vijaya Satish Sekhar Pilli; Brian C Cooley; Rima Chattopadhyay; Pamela R Westmark; Todd Getz; David Paul; Wolfgang Bergmeier; John P Sheehan; Rinku Majumder Journal: Arterioscler Thromb Vasc Biol Date: 2018-02-01 Impact factor: 8.311
Authors: Jeremy P Wood; Matthew W Bunce; Susan A Maroney; Paula B Tracy; Rodney M Camire; Alan E Mast Journal: Proc Natl Acad Sci U S A Date: 2013-10-14 Impact factor: 11.205
Authors: Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: AIDS Date: 2014-05-15 Impact factor: 4.177